ARTICLE | Company News
Abbott submits Zemplar NDA
August 2, 2004 7:00 AM UTC
ABT submitted an NDA for Zemplar paricalcitol capsules to treat secondary hyperparathyroidism (SHPT). SHPT is a complication of chronic kidney disease. An injectable form of Zemplar, a third-generatio...